Sequencing.com, a biotech company offering the world’s largest platform for whole genome sequencing and personalized health insights, announced a strategic partnership with PGxAI, a leader in AI-driven pharmacogenomics. This collaboration will transform the pharmacogenomics field by combining cutting-edge genomic insights with real-world healthcare applications, ultimately enhancing patient outcomes and reducing adverse drug reactions.
As part of this initiative, PGxAI will roll out a suite of pharmacogenomic reports on Sequencing.com that provide personalized drug implications based on an individual’s genomic data. They directly address a critical healthcare need — reducing adverse drug reaction incidences, a leading cause of unnecessary healthcare costs and patient harm. The reports cover over 730 drugs and 40 genes — offering up to five times the coverage of competitors.
“Adverse drug reactions account for over $150 billion in excess healthcare costs annually in the U.S.,” said Allan Gobbs, PGxAI Executive Chairman and Co-Founder. “Studies indicate that pharmacogenomics can reduce these incidents by 30%, representing a significant opportunity to optimize healthcare costs and make treatments more affordable and effective.”
Also Read: Seek Labs Debuts Equipment-Free Molecular MTB Prototype on SeekIt
Dr. Brandon Colby, Sequencing.com Founder and CEO, added, “The demand for pharmacogenomic testing is rapidly growing. PGxAI’s scientific rigor and comprehensive data coverage provide unmatched value to our customers, further driving the precision health movement.”
“More than 99% of individuals carry clinically relevant drug-gene variations,” said Dr. Mike Zack, PGxAI CEO and Co-Founder. “Leveraging this information enables safer, more effective treatment regimens, making precision pharmacogenomics an immediate reality for modern healthcare.”
PGxAI’s reports seamlessly integrate with major reporting formats from clinically actionable consumer genetic testing services. These integrations allow users to effortlessly upload their genetic data, unlocking actionable insights linked to FDA guidelines and leading pharmacogenomics consortiums. These reports also represent new revenue opportunities for laboratories working with genomic data. Zack emphasized, “Our reports are plug-and-play for genomic labs, offering new revenue streams while delivering measurable benefits for patients.”
Source: Businesswire